Hello, everyone, and how are you this morning? We are doing just fine, thank you, despite a bit of freezing rain that made for a challenging trip to the local schoolhouse, where we deposited the short person for another day of learning. Naturally, such adventures call for cups of stimulation. We are once again favoring maple pecan. As always, feel free to join us. Remember, no prescription is required, which means we do not demand rebates. Meanwhile, here are your tidbits. Hope you have a smashing day and do remember us when saucy developments arise.

The Sackler family withdrew more than $10 billion from Purdue Pharma from 2008 t0 2017, the New York Times writes, citing an audit filed in U.S. bankruptcy court. The money, which was distributed among trusts and overseas holdings companies, is more than eight times what the family took from Purdue in the 13 years after OxyContin was approved in 1995. The audit is likely to renew questions about how much the Sacklers should pay to resolve some 2,800 lawsuits that seek to hold Purdue accountable for the opioid crisis (click on #654).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy